NCT02743611 2023-10-05
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Bellicum Pharmaceuticals
Phase 1/2 Terminated
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
M.D. Anderson Cancer Center